The role of carfilzomib in relapsed/refractory multiple myeloma

被引：15
作者：
Yee, Andrew J. [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, 55 Fruit St, Boston, MA 02114 USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷
关键词：
carfilzomib; multiple myeloma; PROTEASOME INHIBITOR CARFILZOMIB; ONCE-WEEKLY CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; SINGLE-AGENT; IRREVERSIBLE INHIBITOR; SURVIVAL ANALYSIS; SAFETY PROFILE; OPEN-LABEL; BORTEZOMIB;
D O I：
10.1177/20406207211019612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
    Uysal, Ayse
    Akad Soyer, Nur
    Ozkan, Melda
    Sahin, Fahri
    Vural, Filiz
    Tobu, Mahmut
    Tombuloglu, Murat
    Saydam, Guray
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (01) : 80 - 83
  • [22] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
  • [23] Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
    Liu, Liping
    Zhao, Ningning
    Xu, Wenjun
    Sheng, Zhixin
    Wang, Lida
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [24] Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
    Chari, Ajai
    Stewart, A. Keith
    Russell, Stuart D.
    Moreau, Philippe
    Herrmann, Joerg
    Banchs, Jose
    Hajek, Roman
    Groarke, John
    Lyon, Alexander R.
    Batty, George N.
    Ro, Sunhee
    Huang, Mei
    Iskander, Karim S.
    Lenihan, Daniel
    BLOOD ADVANCES, 2018, 2 (13) : 1633 - 1644
  • [25] Carfilzomib boosted combination therapy for relapsed multiple myeloma
    Steiner, Raphael E.
    Manasanch, Elisabet E.
    ONCOTARGETS AND THERAPY, 2017, 10 : 895 - 907
  • [26] Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
    Boccon-Gibod, Clementine
    Talbot, Alexis
    Le Bras, Fabien
    Frenzel, Laurent
    Royer, Bruno
    Harel, Stephanie
    Lombion, Naelle
    Belhadj, Karim
    Cuccuini, Wendy
    Arnulf, Bertrand
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E73 - E76
  • [27] Carfilzomib in multiple myeloma
    Andreu-Vieyra, Claudia
    Berenson, James R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (11) : 1685 - 1699
  • [28] Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
    Terpos, Evangelos
    Zambello, Renato
    Leleu, Xavier
    Kuehr, Thomas
    Badelita, Sorina N.
    Katodritou, Eirini
    Brescianini, Alessandra
    Liang, Tony
    Wetten, Sally
    Caers, Jo
    CANCERS, 2022, 14 (21)
  • [29] The role of carfilzomib in treatment of newly diagnosed multiple myeloma
    Strifler, Susanne
    Knop, Stefan
    FUTURE ONCOLOGY, 2018, 14 (30) : 3123 - 3134
  • [30] Treatment of relapsed and refractory multiple myeloma
    Lee, Ji Hyun
    Kim, Sung-Hyun
    BLOOD RESEARCH, 2020, 55 : 43 - 53
12345